IL112348A - 3-amino-2-phenylpiperidine and (2s, 3s)-3-amino-2- phenylpiperidine - Google Patents

3-amino-2-phenylpiperidine and (2s, 3s)-3-amino-2- phenylpiperidine

Info

Publication number
IL112348A
IL112348A IL112348A IL11234890A IL112348A IL 112348 A IL112348 A IL 112348A IL 112348 A IL112348 A IL 112348A IL 11234890 A IL11234890 A IL 11234890A IL 112348 A IL112348 A IL 112348A
Authority
IL
Israel
Prior art keywords
cis
nmr
phenylpiperidine
methoxybenzylamino
formula
Prior art date
Application number
IL112348A
Other languages
English (en)
Inventor
Manoj C Desai
Terry J Rosen
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IL112348A publication Critical patent/IL112348A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
IL112348A 1990-01-04 1990-12-28 3-amino-2-phenylpiperidine and (2s, 3s)-3-amino-2- phenylpiperidine IL112348A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US1990/000116 WO1991009844A1 (en) 1990-01-04 1990-01-04 Substance p antagonists
IL96821A IL96821A (en) 1990-01-04 1990-12-28 3-aminopiperidine derivatives, related nitrogen containing heterocycles and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
IL112348A true IL112348A (en) 1998-06-15

Family

ID=22220614

Family Applications (3)

Application Number Title Priority Date Filing Date
IL112348A IL112348A (en) 1990-01-04 1990-12-28 3-amino-2-phenylpiperidine and (2s, 3s)-3-amino-2- phenylpiperidine
IL96821A IL96821A (en) 1990-01-04 1990-12-28 3-aminopiperidine derivatives, related nitrogen containing heterocycles and pharmaceutical compositions containing them
IL11234895A IL112348A0 (en) 1990-01-04 1995-01-16 3-Amino-2-phenyl- piperidine and (2s, 3s)-3-amino-2-phenylpiperidine

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL96821A IL96821A (en) 1990-01-04 1990-12-28 3-aminopiperidine derivatives, related nitrogen containing heterocycles and pharmaceutical compositions containing them
IL11234895A IL112348A0 (en) 1990-01-04 1995-01-16 3-Amino-2-phenyl- piperidine and (2s, 3s)-3-amino-2-phenylpiperidine

Country Status (27)

Country Link
EP (2) EP0436334B1 (pl)
JP (1) JPH0757748B2 (pl)
KR (1) KR930009441B1 (pl)
CN (2) CN1035944C (pl)
AT (1) ATE115127T1 (pl)
AU (1) AU625511B2 (pl)
BR (1) BR9100016A (pl)
CA (1) CA2033497C (pl)
CZ (1) CZ289485B6 (pl)
DE (1) DE69014848T2 (pl)
DK (1) DK0436334T3 (pl)
ES (1) ES2064667T3 (pl)
FI (2) FI114096B (pl)
GR (1) GR3014940T3 (pl)
HU (5) HU220602B1 (pl)
IE (1) IE63770B1 (pl)
IL (3) IL112348A (pl)
MY (1) MY105438A (pl)
NO (1) NO178187C (pl)
NZ (1) NZ236581A (pl)
PL (5) PL164205B1 (pl)
PT (1) PT96405B (pl)
RU (1) RU2105758C1 (pl)
UA (1) UA41251C2 (pl)
WO (1) WO1991009844A1 (pl)
YU (1) YU48026B (pl)
ZA (1) ZA9136B (pl)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830863A (en) * 1988-06-20 1998-11-03 Merrell Pharmaceuticals Inc. Neurokinin A antagonists
US6218364B1 (en) 1988-06-20 2001-04-17 Scott L. Harbeson Fluorinated neurokinin A antagonists
US5332817A (en) * 1990-01-04 1994-07-26 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles
US5232929A (en) * 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
HU226529B1 (en) * 1990-05-31 2009-03-30 Pfizer Process for preparing substituted piperidines
US5364943A (en) * 1991-11-27 1994-11-15 Pfizer Inc. Preparation of substituted piperidines
HUT62891A (en) * 1990-06-01 1993-06-28 Pfizer Process for producing 3-amino-2-arylquinuclidine compounds and pharmaceuticql composition comprising such compounds
CA2086434C (en) * 1990-07-23 1998-09-22 John A. Lowe, Iii Quinuclidine derivatives
EP0581777A1 (en) * 1991-03-26 1994-02-09 Pfizer Inc. Stereoselective preparation of substituted piperidines
US5716965A (en) * 1991-05-22 1998-02-10 Pfizer Inc. Substituted 3-aminoquinuclidines
PL170516B1 (en) * 1991-06-20 1996-12-31 Pfizer Method of obtaining novel derivatives of fluoroalkoxy benzylaminic compounds of piperidine
TW202432B (pl) * 1991-06-21 1993-03-21 Pfizer
EP0528495A1 (en) * 1991-08-20 1993-02-24 Merck Sharp & Dohme Ltd. Azacyclic compounds, processes for their preparation and pharmaceutical compositions containing them
PT533280E (pt) * 1991-09-20 2001-01-31 Glaxo Group Ltd Novas utilizacoes medicas para antagonistas de taquiquinina
GB9201179D0 (en) * 1992-01-21 1992-03-11 Glaxo Group Ltd Chemical compounds
FR2688219B1 (fr) 1992-03-03 1994-07-08 Sanofi Elf Sels d'ammonium quaternaires de composes aromatiques amines, leur preparation et compositions pharmaceutiques les contenant.
US5444074A (en) * 1992-04-15 1995-08-22 Merck Sharp & Dohme Limited Piperidine tachykinin receptor antagonists
WO1993021181A1 (en) * 1992-04-15 1993-10-28 Merck Sharp & Dohme Limited Azacyclic compounds
CA2134964C (en) * 1992-05-18 1997-12-30 Manoj C. Desai Bridged aza-bicyclic derivatives as substance p antagonists
US5637699A (en) * 1992-06-29 1997-06-10 Merck & Co., Inc. Process for preparing morpholine tachykinin receptor antagonists
US5719147A (en) * 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
US6048859A (en) * 1992-06-29 2000-04-11 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
CA2099233A1 (en) * 1992-06-29 1993-12-30 Conrad P. Dorn Morpholine and thiomorpholine tachykinin receptor antagonists
ES2124318T3 (es) * 1992-07-28 1999-02-01 Merck Sharp & Dohme Compuestos azaciclicos.
AU4396193A (en) * 1992-08-04 1994-03-03 Pfizer Inc. 3-benzylamino-2-phenyl-piperidine derivatives as substance p receptor antagonists
GB9216911D0 (en) * 1992-08-10 1992-09-23 Merck Sharp & Dohme Therapeutic agents
US5387595A (en) * 1992-08-26 1995-02-07 Merck & Co., Inc. Alicyclic compounds as tachykinin receptor antagonists
AU4973693A (en) * 1992-09-10 1994-03-29 Merck Sharp & Dohme Limited Alcohols and ethers with aromatic substituents as tachykinin-antagonists
GB9220286D0 (en) * 1992-09-25 1992-11-11 Merck Sharp & Dohme Therapeutic agents
US5344830A (en) * 1992-12-10 1994-09-06 Merck & Co., Inc. N,N-diacylpiperazine tachykinin antagonists
CA2150123C (en) * 1992-12-10 2004-12-07 Harry R. Howard Aminomethylene substituted non-aromatic heterocycles
US6369074B1 (en) * 1992-12-10 2002-04-09 Pfizer Inc. Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists
US5830854A (en) * 1992-12-14 1998-11-03 Merck Sharp & Dohme, Limited Method of treating cystic fibrosis using a tachykinin receptor antagonist
GB9300051D0 (en) * 1993-01-04 1993-03-03 Merck Sharp & Dohme Therapeutic agents
JPH08506823A (ja) * 1993-02-18 1996-07-23 メルク シヤープ エンド ドーム リミテツド アザ環式化合物、該化合物を含む組成物及びタキキニン拮抗剤としての該化合物の使用
US5496833A (en) * 1993-04-13 1996-03-05 Merck Sharp & Dohme Limited Piperidine tachykinin receptor antagonists
ATE155456T1 (de) * 1993-05-28 1997-08-15 Pfizer Verfahren zur herstellung und optischen auflösung von 2-phenyl-3-aminopiperidine
US5348955A (en) * 1993-06-22 1994-09-20 Merck & Co., Inc. N,N-diacylpiperazines
GB9317104D0 (en) * 1993-08-17 1993-09-29 Zeneca Ltd Therapeutic heterocycles
AU7082194A (en) * 1993-09-17 1995-04-03 Pfizer Inc. Heteroarylamino and heteroarylsulfonamido substituted 3-benzylaminomethyl piperidines and related compounds
DE69433744T2 (de) * 1993-09-17 2004-10-14 Pfizer Inc. 3-amino-5-carboxy-substituierte piperidine und 3-amino-4-carboxy-substituierte pyrrolidine als tachykinin-antagonisten
US6083943A (en) * 1993-09-17 2000-07-04 Pfizer Inc Substituted azaheterocyclecarboxylic acid
IL111002A (en) * 1993-09-22 1998-09-24 Glaxo Group Ltd Piperidine derivatives their preparation and pharmaceutical compositions containing them
TW263498B (pl) * 1993-11-10 1995-11-21 Takeda Pharm Industry Co Ltd
WO1995020575A1 (en) * 1994-01-28 1995-08-03 Merck Sharp & Dohme Limited Aralkylamino substituted azacyclic therapeutic agents
US5610165A (en) * 1994-02-17 1997-03-11 Merck & Co., Inc. N-acylpiperidine tachykinin antagonists
TW385308B (en) * 1994-03-04 2000-03-21 Merck & Co Inc Prodrugs of morpholine tachykinin receptor antagonists
GB9408872D0 (en) * 1994-05-03 1994-06-22 Zeneca Ltd Heterocyclic compounds
GB9418545D0 (en) * 1994-09-15 1994-11-02 Merck Sharp & Dohme Therapeutic agents
FR2725900B1 (fr) * 1994-10-21 1997-07-18 Sanofi Sa Utilisation d'antagonistes des recepteurs nk1 pour la preparation de medicaments a action cardioregulatrice
EP0709375B1 (en) * 1994-10-25 2005-05-18 AstraZeneca AB Therapeutic heterocycles
US5998444A (en) * 1995-10-24 1999-12-07 Zeneca Ltd. Piperidinyl compounds as NK1 or NK2 antagonists
US6008223A (en) * 1994-10-27 1999-12-28 Zeneca Limited Therapeutic compounds
FR2728165A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene
FR2728166A1 (fr) 1994-12-19 1996-06-21 Oreal Composition topique contenant un antagoniste de substance p
FR2728169A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales
FR2729952B1 (fr) * 1995-01-30 1997-04-18 Sanofi Sa Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2729954B1 (fr) * 1995-01-30 1997-08-01 Sanofi Sa Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2741262B1 (fr) 1995-11-20 1999-03-05 Oreal Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene
DK0780375T3 (da) 1995-12-21 2002-10-07 Pfizer 3-((5-substitueret benzyl)amino)-2-phenylpiperidiner som substans P-antagonister
WO1998014193A1 (en) * 1996-10-04 1998-04-09 Alcon Laboratories, Inc. The use of a substance p antagonist for the manufacture of a medicament for the treatment of ocular pain
US5750549A (en) * 1996-10-15 1998-05-12 Merck & Co., Inc. Cycloalkyl tachykinin receptor antagonists
CA2287487A1 (en) * 1997-04-24 1998-10-29 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating eating disorders
GB9716463D0 (en) * 1997-08-04 1997-10-08 Merck Sharp & Dohme Therapeutic agents
AU738047B2 (en) * 1997-08-04 2001-09-06 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating mania
GB9716457D0 (en) * 1997-08-04 1997-10-08 Merck Sharp & Dohme Therapeutic agents
AU737019B2 (en) * 1997-08-04 2001-08-09 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating aggressive behaviour disorders
GB9816897D0 (en) * 1998-08-04 1998-09-30 Merck Sharp & Dohme Therapeutic use
JP4510290B2 (ja) * 1998-08-25 2010-07-21 ノバルティス アーゲー 慢性疲労症候群および／または線維筋痛の処置のためのサブスタンスｐアンタゴニストの使用および慢性疲労症候群の処置のためのｎｋ−１レセプターアンタゴニストの使用
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
PT1246806E (pt) 1999-11-03 2008-04-03 Amr Technology Inc Tetra-hidroisoquinolinas aril- e heteroaril-substituídas e sua utilização no bloqueio da recaptação de norepinefrina, dopamina e serotonina.
EA005893B1 (ru) 2000-03-21 2005-06-30 Смитклайн Бичам Корпорейшн Ингибиторы протеаз
CN100430401C (zh) 2000-07-11 2008-11-05 Amr科技公司 新的4-苯基取代的四氢异喹啉类化合物及其治疗用途
WO2002028853A1 (en) * 2000-10-02 2002-04-11 Tanabe Seiyaku Co., Ltd. Benzylamine compound, process for producing the same, and intermediate therefor
US6709651B2 (en) 2001-07-03 2004-03-23 B.M.R.A. Corporation B.V. Treatment of substance P-related disorders
AU2002360046A1 (en) * 2001-12-28 2003-07-24 Takeda Chemical Industries, Ltd. Nitrogenous cyclic ketone derivative, process for producing the same, and use
US7220098B2 (en) 2003-05-27 2007-05-22 General Electric Company Wear resistant variable stator vane assemblies
US7541357B2 (en) 2004-07-15 2009-06-02 Amr Technology, Inc. Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US7868014B2 (en) 2004-10-18 2011-01-11 Eli Lilly And Company 1-(hetero)aryl-3-amino-pyrrolidine derivatives for use as mGluR3 antagonists
GB0423356D0 (en) * 2004-10-21 2004-11-24 Merck Sharp & Dohme Therapeutic agents
US7543992B2 (en) 2005-04-28 2009-06-09 General Electric Company High temperature rod end bearings
ES2382814T3 (es) 2005-05-17 2012-06-13 Merck Sharp & Dohme Ltd. Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer
EP1904069B1 (en) 2005-07-15 2018-06-13 Albany Molecular Research, Inc. Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
WO2007041052A2 (en) 2005-09-29 2007-04-12 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
EP2083831B1 (en) 2006-09-22 2013-12-25 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
DK2805945T3 (da) 2007-01-10 2019-07-15 Msd Italia Srl Amid-substituerede indazoler som poly(adp-ribose)polymerase- (parp) hæmmere
EP2117538A1 (en) 2007-01-24 2009-11-18 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
EP3103791B1 (en) 2007-06-27 2018-01-31 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
CA2717509A1 (en) 2008-03-03 2009-09-11 Tiger Pharmatech Tyrosine kinase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
AR071997A1 (es) 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
AU2010209816A1 (en) * 2009-01-27 2011-08-11 F. Hoffmann-La Roche Ag Aroylamino - and heteroaroylamino-substituted piperidines as GlyT-1 inhibitors
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
CA2760837C (en) 2009-05-12 2018-04-03 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-.alpha.]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
ES2446971T3 (es) 2009-05-12 2014-03-11 Albany Molecular Research, Inc. Tetrahidroisoquinolinas sustituidas con arilo, heteroarilo, y heterociclo y su uso
JP5739415B2 (ja) 2009-05-12 2015-06-24 ブリストル−マイヤーズ スクウィブ カンパニー （Ｓ）−７−（［１，２，４］トリアゾロ［１，５−ａ］ピリジン−６−イル）−４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロイソキノリンの結晶形態およびその使用
PH12012500713A1 (en) 2009-10-14 2012-11-26 Merck Sharp & Dohme Substituted piperidines that increase p53 activity and the uses thereof
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
US8518907B2 (en) 2010-08-02 2013-08-27 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
RU2624045C2 (ru) 2010-08-17 2017-06-30 Сирна Терапьютикс,Инк ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP3327125B1 (en) 2010-10-29 2020-08-05 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
JP2014514321A (ja) 2011-04-21 2014-06-19 メルク・シャープ・アンド・ドーム・コーポレーション インスリン様増殖因子１受容体阻害剤
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3358013B1 (en) 2012-05-02 2020-06-24 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
US9233979B2 (en) 2012-09-28 2016-01-12 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
ME02925B (me) 2012-11-28 2018-04-20 Merck Sharp & Dohme Kompozicije i postupci za liječenje kancera
CA2895504A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
WO2018071283A1 (en) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US11098059B2 (en) 2017-11-08 2021-08-24 Merck Sharp & Dohme Corp. PRMT5 inhibitors
JP2021514976A (ja) * 2018-02-26 2021-06-17 オスペダーレ・サン・ラッファエーレ・エッセエッレエッレ 眼痛の治療における使用のためのｎｋ−１拮抗薬
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
AU2019317549A1 (en) 2018-08-07 2021-02-25 Msd International Gmbh PRMT5 inhibitors
EP3833668B1 (en) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE535451A (pl) * 1954-02-05
GB1060160A (en) * 1964-08-05 1967-03-01 Allen & Hanburys Ltd 4-phenylpiperidine derivatives
US3560510A (en) * 1969-03-05 1971-02-02 Aldrich Chem Co Inc 2-benzhydrylquinuclidines
US3992389A (en) * 1970-09-03 1976-11-16 John Wyeth & Brother Limited Heterocyclic compounds
WO1990005525A1 (en) * 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine derivatives as substance p antagonists
HU226529B1 (en) * 1990-05-31 2009-03-30 Pfizer Process for preparing substituted piperidines

Also Published As

Publication number Publication date
NO910016L (no) 1991-07-05
HUT60719A (en) 1992-10-28
PL164244B1 (en) 1994-07-29
CA2033497A1 (en) 1991-07-05
CN1053060A (zh) 1991-07-17
KR930009441B1 (ko) 1993-10-04
HU910006D0 (en) 1991-08-28
NZ236581A (en) 1992-10-28
CZ289485B6 (cs) 2002-02-13
IE63770B1 (en) 1995-06-14
PL293392A1 (en) 1992-07-13
YU48026B (sh) 1996-10-09
IE910007A1 (en) 1991-07-17
FI20040479A7 (fi) 2004-04-01
HUT68179A (en) 1995-05-29
CN1045595C (zh) 1999-10-13
NO178187C (no) 1996-02-07
PT96405B (pt) 1998-06-30
HUT68130A (en) 1995-05-29
RU2105758C1 (ru) 1998-02-27
MY105438A (en) 1994-10-31
DE69014848D1 (de) 1995-01-19
PL293390A1 (en) 1992-07-13
DK0436334T3 (da) 1995-02-13
EP0558156A2 (en) 1993-09-01
HUT68180A (en) 1995-05-29
ZA9136B (en) 1992-08-26
EP0436334A3 (en) 1992-05-27
YU491A (sh) 1994-01-20
DE69014848T2 (de) 1995-05-04
AU625511B2 (en) 1992-07-16
UA41251C2 (uk) 2001-09-17
ATE115127T1 (de) 1994-12-15
AU6862191A (en) 1991-07-18
JPH04103570A (ja) 1992-04-06
NO910016D0 (no) 1991-01-03
PL293391A1 (en) 1992-07-13
PT96405A (pt) 1991-10-15
BR9100016A (pt) 1991-10-22
PL164203B1 (pl) 1994-06-30
PL288592A1 (en) 1992-06-15
WO1991009844A1 (en) 1991-07-11
IL112348A0 (en) 1995-03-30
PL163967B1 (pl) 1994-06-30
HU222724B1 (hu) 2003-09-29
IL96821A (en) 1997-03-18
ES2064667T3 (es) 1995-02-01
NO178187B (no) 1995-10-30
EP0558156A3 (en) 1993-10-06
JPH0757748B2 (ja) 1995-06-21
CS1091A3 (en) 1991-08-13
CN1087083A (zh) 1994-05-25
CN1035944C (zh) 1997-09-24
PL293389A1 (en) 1992-07-13
IL96821A0 (en) 1991-09-16
PL164205B1 (en) 1994-06-30
FI910034A0 (fi) 1991-01-03
EP0436334A2 (en) 1991-07-10
KR910014350A (ko) 1991-08-31
EP0436334B1 (en) 1994-12-07
GR3014940T3 (en) 1995-05-31
CA2033497C (en) 1997-01-07
PL164204B1 (pl) 1994-06-30
FI910034L (fi) 1991-07-05
FI114096B (fi) 2004-08-13
HU220602B1 (hu) 2002-03-28

Similar Documents

Publication Publication Date Title
US5232929A (en) 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
AU625511B2 (en) 3-aminopiperidine derivatives and related nitrogen containing heterocycles
CA2123403C (en) Acyclic ethylenediamine derivatives as substance p receptor antagonists
EP0699199B1 (en) Heteroatom substituted alkyl benzylaminoquinuclidines as substance p antagonists
US5744480A (en) Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
CA2109415C (en) Substituted 3-aminoquinuclidines
AP643A (en) Substituted benzylaminopiperidine compounds.
US5332817A (en) 3-aminopiperidine derivatives and related nitrogen containing heterocycles
EP0654029A1 (en) 3-benzylamino-2-phenyl-piperidine derivatives as substance p receptor antagonists
IE913396A1 (en) Fused ring analogs of nitrogen containing nonaromatic heterocycles
CZ285409B6 (cs) Polycyklické aminosloučeniny a jejich enantiomery, způsob jejich přípravy a farmaceutické prostředky, které je obsahují
JP2005537293A (ja) Ｎ−［フェニル（ピペリジン−２−イル）メチル］ベンズアミド誘導体、その製造法、およびその治療用途
US5716965A (en) Substituted 3-aminoquinuclidines
JP2719063B2 (ja) 置換３−アミノキヌクリジンｐ物質拮抗剤

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees